{"id":24299,"date":"2022-11-16T01:54:00","date_gmt":"2022-11-15T17:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24299"},"modified":"2025-01-31T01:59:44","modified_gmt":"2025-01-30T17:59:44","slug":"simcere-pharmaceuticals-licenses-idorsias-insomnia-therapy-daridorexant-for-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24299","title":{"rendered":"Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China"},"content":{"rendered":"\n

China-based Simcere Pharmaceutical Group (HKG: 2096<\/a>) has announced the establishment of a licensing agreement with Swiss firm Idorsia Ltd, securing exclusive development and commercialization rights to Idorsia\u2019s insomnia therapy daridorexant in Greater China, including mainland China, Hong Kong, and Macau. The agreement also includes clinical research and development (R&D) activities. Simcere will pay Idorsia USD 30 million upfront, with an additional commitment of USD 20 million in milestone payments and low double-digit royalties based on future sales.<\/p>\n\n\n\n

Daridorexant Profile<\/strong>
Daridorexant is a dual orexin receptor antagonist that specifically blocks the neuropeptide orexin, which promotes arousal, without inducing sleep by generally calming the brain. This mechanism reduces the wake-up drive and induces sleep without altering the proportion of sleep stages. Phase III clinical data has demonstrated that daridorexant significantly improved sleep onset, sleep maintenance, and total sleep time compared with a placebo. Importantly, the proportion of sleep stages remained unchanged across all treatment groups, a significant difference from the results reported by benzodiazepine receptor agonists. Daridorexant has been approved in the United States and Europe in January and April 2022, respectively, for improving night sleep and daytime function in adults with chronic insomnia.<\/p>\n\n\n\n

Future Implications<\/strong>
The licensing agreement between Simcere and Idorsia marks a significant step in expanding access to innovative insomnia treatments in Greater China. By leveraging Idorsia\u2019s expertise and Simcere\u2019s local market presence, the partnership aims to address the significant unmet medical needs in the treatment of chronic insomnia. This move positions Simcere to enhance its portfolio of neurology-focused therapies and contribute to improving patient outcomes in the region.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,87,1099,2489,271],"class_list":["post-24299","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-chronic-disease","tag-hkg-2096","tag-idorsia","tag-simcere-pharmaceutical"],"yoast_head":"\nSimcere Pharmaceuticals Licenses Idorsia's Insomnia Therapy Daridorexant for Greater China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with Swiss firm Idorsia Ltd, securing exclusive development and commercialization rights to Idorsia\u2019s insomnia therapy daridorexant in Greater China, including mainland China, Hong Kong, and Macau. The agreement also includes clinical research and development (R&D) activities. Simcere will pay Idorsia USD 30 million upfront, with an additional commitment of USD 20 million in milestone payments and low double-digit royalties based on future sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24299\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Pharmaceuticals Licenses Idorsia's Insomnia Therapy Daridorexant for Greater China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24299\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T17:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-30T17:59:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24299#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24299\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China\",\"datePublished\":\"2022-11-15T17:54:00+00:00\",\"dateModified\":\"2025-01-30T17:59:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24299\"},\"wordCount\":276,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Chronic disease\",\"HKG: 2096\",\"Idorsia\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24299#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24299\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24299\",\"name\":\"Simcere Pharmaceuticals Licenses Idorsia's Insomnia Therapy Daridorexant for Greater China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-15T17:54:00+00:00\",\"dateModified\":\"2025-01-30T17:59:44+00:00\",\"description\":\"China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with Swiss firm Idorsia Ltd, securing exclusive development and commercialization rights to Idorsia\u2019s insomnia therapy daridorexant in Greater China, including mainland China, Hong Kong, and Macau. The agreement also includes clinical research and development (R&D) activities. Simcere will pay Idorsia USD 30 million upfront, with an additional commitment of USD 20 million in milestone payments and low double-digit royalties based on future sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24299#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24299\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24299#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Pharmaceuticals Licenses Idorsia's Insomnia Therapy Daridorexant for Greater China - Insight, China's Pharmaceutical Industry","description":"China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with Swiss firm Idorsia Ltd, securing exclusive development and commercialization rights to Idorsia\u2019s insomnia therapy daridorexant in Greater China, including mainland China, Hong Kong, and Macau. The agreement also includes clinical research and development (R&D) activities. Simcere will pay Idorsia USD 30 million upfront, with an additional commitment of USD 20 million in milestone payments and low double-digit royalties based on future sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24299","og_locale":"en_US","og_type":"article","og_title":"Simcere Pharmaceuticals Licenses Idorsia's Insomnia Therapy Daridorexant for Greater China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24299","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-15T17:54:00+00:00","article_modified_time":"2025-01-30T17:59:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24299#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24299"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China","datePublished":"2022-11-15T17:54:00+00:00","dateModified":"2025-01-30T17:59:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24299"},"wordCount":276,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Chronic disease","HKG: 2096","Idorsia","Simcere Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24299#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24299","url":"https:\/\/flcube.com\/?p=24299","name":"Simcere Pharmaceuticals Licenses Idorsia's Insomnia Therapy Daridorexant for Greater China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-15T17:54:00+00:00","dateModified":"2025-01-30T17:59:44+00:00","description":"China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with Swiss firm Idorsia Ltd, securing exclusive development and commercialization rights to Idorsia\u2019s insomnia therapy daridorexant in Greater China, including mainland China, Hong Kong, and Macau. The agreement also includes clinical research and development (R&D) activities. Simcere will pay Idorsia USD 30 million upfront, with an additional commitment of USD 20 million in milestone payments and low double-digit royalties based on future sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24299#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24299"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24299#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24299"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24299\/revisions"}],"predecessor-version":[{"id":24301,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24299\/revisions\/24301"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}